Icon-Pfizer link to boost revenue

ICON’S alliance with Pfizer Inc is “likely” to generate in excess of $100 million (€69.34m) in revenue a year, and potentially “significantly more,” chief executive Peter Gray said.

“It should mean a significant extra amount of business for the next couple of years,” as the deal “builds up,” said Mr Gray in an interview. The company expects to boost its capacity to cope with the influx of new business, he said.

Icon said on May 26 it will serve as one of two preferred providers of clinical trial implementation services for Pfizer.